Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B virus vaccine (recombinant)
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Hepatitis B virus vaccine (recombinant) is a non-infectious recombinant protein subunit vaccine used to prevent infection by all known subtypes of the hepatitis B virus. The active component is the purified recombinant hepatitis B surface antigen (HBsAg), produced in yeast cells (*Saccharomyces cerevisiae*) using recombinant DNA technology. The vaccine stimulates active immunity by inducing specific humoral antibodies against HBsAg; an anti-HBs antibody titre above 10 IU/L correlates with protection from infection. It is indicated for use in individuals of all ages and is a cornerstone of global public health efforts to reduce the incidence and complications of acute and chronic hepatitis B infection[1][2][4][5].
- Brand names
- Engerix-BRecombivax HBHeplisav-B
- Other names
- hepatitis B vaccine (recombinant)HBsAghepatitis B surface antigenhepatitis B surface antigen (recombinant)hepatitis B surface antigen vaccinehepatitis-B surface antigen
02
Targets
HBsAg (Hepatitis B surface antigen)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on hepatitis B virus vaccine (recombinant).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B virus vaccine (recombinant).